Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1968 4
1969 11
1970 4
1971 8
1972 7
1973 6
1974 13
1975 5
1976 8
1977 7
1978 5
1979 10
1980 6
1981 6
1982 13
1983 13
1984 11
1985 18
1986 20
1987 8
1988 19
1989 28
1990 38
1991 41
1992 60
1993 79
1994 95
1995 90
1996 71
1997 118
1998 120
1999 105
2000 118
2001 86
2002 133
2003 155
2004 149
2005 145
2006 164
2007 206
2008 201
2009 238
2010 292
2011 302
2012 302
2013 333
2014 372
2015 377
2016 366
2017 343
2018 376
2019 356
2020 379
2021 334
2022 178
2023 184
2024 54

Text availability

Article attribute

Article type

Publication date

Search Results

6,376 results

Results by year

Filters applied: . Clear all
Page 1
Cancer statistics, 2022.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Siegel RL, et al. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. CA Cancer J Clin. 2022. PMID: 35020204 Free article.
Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. ...More targeted cancer control interventions and investment in improved early
Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Ilic D, et al. BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519. BMJ. 2018. PMID: 30185521 Free PMC article.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSA screening with usual care in men without a diagnosis of prostate cancer. ...CONCLUSIONS: At best, screening for prostate cancer leads to a small …
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSA screening with usual care in men without a …
Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials.
Bretthauer M, Wieszczy P, Løberg M, Kaminski MF, Werner TF, Helsingen LM, Mori Y, Holme Ø, Adami HO, Kalager M. Bretthauer M, et al. JAMA Intern Med. 2023 Nov 1;183(11):1196-1203. doi: 10.1001/jamainternmed.2023.3798. JAMA Intern Med. 2023. PMID: 37639247
MEDLINE and the Cochrane library databases were searched, and the last search was performed October 12, 2022. STUDY SELECTION: Mammography screening for breast cancer; colonoscopy, sigmoidoscopy, or fecal occult blood testing (FOBT) for colorectal cancer; com …
MEDLINE and the Cochrane library databases were searched, and the last search was performed October 12, 2022. STUDY SELECTION: Mammography …
Prostate Cancer Screening.
Catalona WJ. Catalona WJ. Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001. Med Clin North Am. 2018. PMID: 29406053 Free PMC article. Review.
During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. ...Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recomme …
During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in …
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.
Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Van Poppel H, et al. Nat Rev Urol. 2022 Sep;19(9):562-572. doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16. Nat Rev Urol. 2022. PMID: 35974245 Review.
In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic prostate cancer and died of the disease; after the introduction of the serum PSA test, randomized controlled prostate cancer screening trials in the US …
In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic prostate cancer and died of the …
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Fenton JJ, et al. JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712. JAMA. 2018. PMID: 29801018 Review.
IMPORTANCE: Prostate cancer is the second leading cause of cancer death among US men. OBJECTIVE: To systematically review evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized pros
IMPORTANCE: Prostate cancer is the second leading cause of cancer death among US men. OBJECTIVE: To systematically revi …
Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.
Barry MJ, Simmons LH. Barry MJ, et al. Med Clin North Am. 2017 Jul;101(4):787-806. doi: 10.1016/j.mcna.2017.03.009. Med Clin North Am. 2017. PMID: 28577627 Review.
More than any other cancer, prostate cancer screening with the prostate-specific antigen (PSA) tests increases the risk a man will have to face a diagnosis of prostate cancer. The best evidence from screening trials s …
More than any other cancer, prostate cancer screening with the prostate-specific antigen (PSA) tests incr …
An Overview of Current Screening and Management Approaches for Prostate Cancer.
Akram ON, Mushtaq G, Kamal MA. Akram ON, et al. Curr Drug Metab. 2015;16(8):713-8. doi: 10.2174/1389200216666150812122430. Curr Drug Metab. 2015. PMID: 26560323 Review.
Prostate cancer is the fourth leading cause of mortality in Australian men. The prevalence and incidence is increasing in both developed and developing nations, thus there is a need for better screening and management of this disorder. While there is n
Prostate cancer is the fourth leading cause of mortality in Australian men. The prevalence and incidence is increasing
Prostate Cancer Screening.
Mulhem E, Fulbright N, Duncan N. Mulhem E, et al. Am Fam Physician. 2015 Oct 15;92(8):683-8. Am Fam Physician. 2015. PMID: 26554408 Free article.
Only one of five randomized controlled trials of PSA screening showed an effect on prostate cancer-specific mortality, and the absolute reduction in deaths from prostate cancer was one per 781 men screened after 13 years of follow- …
Only one of five randomized controlled trials of PSA screening showed an effect on prostate cancer-specific mortalit
Population screening for prostate cancer: an overview of available studies and meta-analysis.
Lumen N, Fonteyne V, De Meerleert G, Ost P, Villeirs G, Mottrie A, De Visschere P, De Troyer B, Oosterlinck W. Lumen N, et al. Int J Urol. 2012 Feb;19(2):100-8. doi: 10.1111/j.1442-2042.2011.02912.x. Epub 2011 Nov 22. Int J Urol. 2012. PMID: 22103653 Review.
The objective of the present review was to evaluate the effect of population-based screening on the incidence of prostate cancer, prostate cancer tumor stage and grade, prostate cancer mortality, and overall mortality
The objective of the present review was to evaluate the effect of population-based screening on the incidence of prostate c
6,376 results